PETACH TIKVA, Israel, Sept. 12, 2017 /PRNewswire/ -- Minerva, a leading provider of anti-evasion technology, today announced the release of the industry's first Endpoint Malware Vaccination module for enterprises. As part of their ground-breaking Anti-Evasion Platform, this new tool helps simulate infection markers across enterprise endpoints to deceive malware into believing it has already infected the system. This unique approach allows Minerva's customers to prevent infections even if other defensive capabilities were unable to block the attack.
"While the idea of malware vaccination has gained some traction among security professionals, deploying infection markers at an enterprise-scale has not been feasible to date. This is because generating these artifacts the traditional way doesn't scale and can be intrusive on the endpoint, potentially impacting the system's performance and conflicting with other security tools," said Lenny Zeltser, Vice President of Products, Minerva. "In contrast, Minerva's ability to simulate, rather than actually create, infection markers allows us to be highly selective regarding how and when we reveal the presence of the vaccine. This enables Minerva to vaccinate endpoints without cluttering the system with unnecessary artifacts, without interfering with legitimate applications and without affecting end-users."
Building upon its core capability to deceive malware into inaction, Minerva has taken the concept of vaccination beyond simply a "cool idea" for lab environments and allowed this technique to be deployed at an enterprise level to expand the endpoint defender's arsenal. Key benefits of the new Endpoint Malware Vaccination tool include:
- Reduced detection time– By using Minerva to simulate the infection marker, the organization is not only alerted when malware attempts to access the marker, but also automatically blocks the attack.
- Contain attacks automatically – By deploying infection markers across all Minerva-protected endpoints, the enterprise can prevent the corresponding malware variants from spreading, with minimal human intervention.
- Collect forensics details about malware that was prevented by the vaccination to enrich threat intelligence.
"Security professionals are used to thinking about indicators of compromise (IOCs) as a way of solely detecting infections after they have taken place," continued Zeltser. "What Minerva delivers with this new tool is an innovative way of turning some IOC attributes into a preventative measure that allows enterprises to avoid infections in the first place by deploying vaccines when appropriate."
Minerva was recently granted a patent for their technology layer that forms the Anti-Evasion Platform. The addition of Endpoint Malware Vaccination to Minerva's solution builds upon this patent and reinforces the unique and innovative way in which the company protects against malware designed to evade existing security tools. Minerva will be hosting a webinar on Wednesday September 27, at 1 p.m. (ET) titled "Safeguarding Endpoints with Malware Vaccination: What it is and why you should care". For more information, and to register for the webinar, please click here.
Minerva is an innovative endpoint security solution provider that protects enterprises from today's stealthiest attacks without the need to detect threats first, all before any damage has been done. Minerva Anti-Evasion Platform blocks unknown threats which evade existing defenses by deceiving the malware and controlling how it perceives its environment. Without relying on signatures, models or behavioral patterns, Minerva's solution deceives the malware and causes it to disarm itself, thwarting it before the need to engage costly security resources.
Headquartered in Petach Tikva, Israel, and with offices in New York and Atlanta, Minerva boost customers' existing defenses without the need to embark upon a costly and risky overhaul of their entire endpoint security architecture. To learn more about Minerva, visit www.minerva-labs.com.
Lumina Communications for Minerva